BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Rivaroxaban

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

999+ PubMed studies analyzed · 331 RCTs · Evidence Score: 74.2

Research Domains

Rivaroxaban has been studied across 13 research domains including ❤️ Cardiovascular, 🫁 Respiratory, 🔬 Oncology, 🫘 Kidney, 😴 Sleep. The primary research focus is ❤️ Cardiovascular with 81% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Rivaroxaban, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Enalapril
2 shared targets
Gabexate
2 shared targets
Sitagliptin
2 shared targets
nafamostat
2 shared targets
Catechin
2 shared targets
darapladib
2 shared targets
Rosmarinic
2 shared targets
Histamine
2 shared targets
Spironolactone
2 shared targets
Mycophenolic
2 shared targets
Loading evidence profile...

This evidence profile for Rivaroxaban is generated deterministically from 999 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.